The Top Ways to Trade the Psychedelics Boom

Psychedelics could be one of the most rewarding opportunities on 2021.

After all, some of these drugs are being found to help treat a range of mental health issues, like obsessive-compulsive disorder, PTSD, opioid addiction, alcoholism, depression, and anxiety. Plus, the US FDA is supportive, calling psilocybin a breakthrough therapy.

Johns Hopkins Medicine launched the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.

New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post. The list of findings goes on and on. Oregon just legalized its use, as did Denver, Oakland, and Santa Cruz.

Psychedelics are becoming so popular there’s a new ETF being launched around them.

On January 26, 2020, the Horizons Psychedelic ETF is expected to launch under the ticker “PSYK” on the NEO Exchange. “The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to ‘invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances,’” as noted in a recent press release from Mind Cure Health.

In addition, “By the end of 2021, I expect the conversation about access to therapeutic outcomes using what were previously known as psychedelics to be a global conversation,” said Bruce Linton, former CEO and founder of Canopy Growth, as quoted by Benzinga.

Along with the ETF, here are some of the top psychedelic stocks to consider.

Mind Medicine (MMEDF)

MMEDF just announced an innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response.

The study will provide an additional research pathway for MindMed’s psychedelic Microdosing Division and will immediately integrate with MindMed’s plans in digital therapeutics through its newly
formed Albert unit for digital medicine. The new study will be conducted in collaboration with Dr. Kim Kuypers of Maastricht University in the Netherlands, a global, leading authority on the micro-dosing of psychedelics.

Compass Pathways (CMPS)

CMPS is establishing its first Centre of Excellence in collaboration with The Sheppard Pratt Institute for Advanced Diagnostics and Therapeutics in Baltimore.

![CMPS Chart](Image)

The Centre of Excellence will model the “clinic of the future”, showcasing the best thinking in science, therapy, technology, and design. Working as a research facility and innovation lab, it will generate evidence to shape therapy models in mental health care, train and certify therapists, conduct clinical trials including proof-of-concept studies, and prototype digital solutions to improve patient experience.

The first wave of research will focus on COMPASS’s investigational COMP360 psilocybin therapy, which comprises administration of COMP360 psilocybin with psychological support from specially trained therapists.

Field Trip Health (FTRPF)

FTRPT “is opening Field Trip Health centers across North America and Europe for the delivery of psychedelic therapies. The Company plans to conduct an observational study to assess whether Field Trip’s ketamine-assisted therapies, which have demonstrated significant efficacy in treating mental health conditions such as depression, anxiety and PTSD, translate into improvements in physical health through a variety of biometric measures collected via WHOOP Strap 3.0 including heart rate variability (HRV), resting heart rate, and overall sleep quality. Field Trip procured WHOOP products and access to additional data insights via a research partnership and enterprise program,” as reported by OTC Stock Review.